Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 638

Sort by

Sort Order Select

Journal Articles

Ublituximab and umbralisib in relapsed/refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia

Matthew Lunning, Julie Vose, Loretta Nastoupil, Nathan Fowler, Jan A. Burger, William G. Wierda, Marshall T. Schreeder, Tanya Siddiqi, Christopher R. Flowers, Jonathon B. Cohen, Peter Sportelli, Hari P. Miskin, Michael S. Weiss, Susan O’Brien

Blood (2019) 134 (21): 1811–1820.

https://doi.org/10.1182/blood.2019002118

Published: 2019

Includes: Supplemental data

Journal Articles

Carfilzomib, Dexamethasone, and Daratumumab Versus Carfilzomib and Dexamethasone for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma (RRMM): Primary Analysis Results from the Randomized, Open-Label, Phase 3 Study Candor (NCT03158688)

Saad Z. Usmani, MDMBBS, Hang Quach, MD, María-Victoria Mateos, Ola Landgren, MD PhD, Xavier Leleu, MD PhD, David S. Siegel, Katja Weisel, Hui Yang, Zandra K. Klippel, MD, Anita Zahlten-Kumeli, Meletios A. Dimopoulos, MD

Blood (2019) 134 (Supplement_2): LBA-6.

https://doi.org/10.1182/blood-2019-132629

Published: 2019

Journal Articles

Cytogenetic and Molecular Marker Associations to Outcomes with Duvelisib and Ofatumumab Treatment in Patients with Relapsed or Refractory CLL/SLL in the DUO Trial

Jennifer R Brown, MD PhD, Kam Sprott, PhD, Santosh Reddy, Stephanie Lustgarten, PhD, David T. Weaver, PhD, Alexey Danilov, MD PhD

Blood (2019) 134 (Supplement_1): 4312.

https://doi.org/10.1182/blood-2019-122491

Published: 2019

Journal Articles

An Adaptive Design Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Emapalumab in Adult Patients with Non-Primary Hemophagocytic Lymphohistiocytosis

Veronica Asnaghi, MD, Maria Ballabio, MD, Philippe Jacqmin, Kathy de Graaf, Cristina De Min, MD

Blood (2019) 134 (Supplement_1): 2333.

https://doi.org/10.1182/blood-2019-123995

Published: 2019

Journal Articles

Incidence of Vaso-Occlusive Crisis Does Not Increase with Achieving Higher Hemoglobin Levels on Voxelotor Treatment or after Discontinuation: Analyses of the HOPE Study

Elliott P. Vichinsky, MD, Paul Telfer, DM, FRCP, Adlette Inati, MD, Margaret Tonda, PharmD, Barbara Tong, PhD, Irene Agodoa, MD, Joshua Lehrer-Graiwer, MD MPhil, FACC, Kenneth I. Ataga, MD

Blood (2019) 134 (Supplement_1): 2313.

https://doi.org/10.1182/blood-2019-129026

Published: 2019

Journal Articles

A Phase II Trial of Azacitidine (AZA) in Combination with Ruxolitinib (RUX) in Myelodysplastic Syndrome/Myeloproliferative Neoplasms (MDS/MPNs)

Blood (2019) 134 (Supplement_1): 4237.

https://doi.org/10.1182/blood-2019-125974

Published: 2019

Journal Articles

Ivosidenib (AG-120) in Patients with IDH1 -Mutant Relapsed/Refractory Myelodysplastic Syndrome: Updated Enrollment of a Phase 1 Dose Escalation and Expansion Study

Blood (2019) 134 (Supplement_1): 4254.

https://doi.org/10.1182/blood-2019-123946

Published: 2019

Journal Articles

Generic Versus Branded Imatinib As Frontline Therapy in Chronic-Phase Chronic Myeloid Leukemia Patients in Italy: A Case-Control Study

Massimiliano Bonifacio, MD, Mario Tiribelli, Gianni Binotto, MD, Maria Cristina Miggiano, Marco Basso, Elisabetta Calistri, Luigi Scaffidi, MD, Rossella Stella, Luca Frison, Roberto Sartori, Marco Ruggeri, Gianpietro Semenzato, Renato Fanin, Mauro Krampera

Blood (2019) 134 (Supplement_1): 5909.

https://doi.org/10.1182/blood-2019-131272

Published: 2019

Journal Articles

Real-World Treatment Patterns and Adverse Events in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib in the UK: A Preliminary Analysis

Jing Xie, Alan Yong, Catherine Waweru, PhD, Thuy Anh Sorof, Ravi K Goyal, MS, Keith L Davis, MA, George Follows, Peter Hillmen, MD PhD

Blood (2019) 134 (Supplement_1): 5885.

https://doi.org/10.1182/blood-2019-123025

Published: 2019

Journal Articles

Social Media Network Utility in Disease Education: Experience from a CML-Disease Awareness Medical Education Program

Ehab L. Atallah, MD, Vamsi Kota, MBBS, Islam Sadek, Andrea Damon, PhD, Ji-May Jen, PharmD, Berna Cakmak, BPharm, Joshua Landy, MD FRCPC, Sharon Vorona, MBBS, Jerald P. Radich, MD

Blood (2019) 134 (Supplement_1): 5842.

https://doi.org/10.1182/blood-2019-124809

Published: 2019

Journal Articles

Pharmacoeconomic Analysis of the Real World Treatment of Chronic Myeloid Leukemia in Chronic Phase of a Brazilian Private Institution Considering the Use of Generic Drugs and Eventual Discontinuation of Treatment

Renato Torrescasana Centrone, Marcelo Bellesso, MD, Rodrigo Santucci Silva, MD, Eliseo J. Sekiya, MD, Milton A. F. Aranha, MD, Isabel Bonafe, Daniela Ferreira Dias, MD, Adelson Alves, MD

Blood (2019) 134 (Supplement_1): 5847.

https://doi.org/10.1182/blood-2019-128629

Published: 2019

Journal Articles

Long-Term Durability of Eltrombopag Clinical Benefit for Advanced Myelodysplastic Syndromes or Acute Myeloid Leukemia and Severe Thrombocytopenia (ASPIRE Part 3)

Moshe Mittelman, MD, Uwe Platzbecker, MD, Boris Afanasyev, MD PhD, Sebastian Grosicki, MD PhD, Maria Socorro O Portella, MD MBA, Zewen Zhu, Dominik Selleslag, MD

Blood (2019) 134 (Supplement_1): 3740.

https://doi.org/10.1182/blood-2019-130309

Published: 2019

Journal Articles

Effect of Avelumab to Immune Response in AML: A Phase I Study of Avelumab in Combination with Decitabine As First Line Treatment of Unfit Patients

Hong Zheng, MD PhD, Shin Mineishi, David F. Claxton, MD, Junjia Zhu, Chenchen Zhao, MD, Bei Jia, MD PhD, W. Christopher Ehmann, MD, Seema Naik, MD, Natthapol Songdej, Raymond J. Hohl

Blood (2019) 134 (Supplement_1): 3939.

https://doi.org/10.1182/blood-2019-125153

Published: 2019

Journal Articles

Phase 1 Dose Escalation and Expansion Study to Determine Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the BET Inhibitor FT-1101 As a Single Agent in Patients with Relapsed or Refractory Hematologic Malignancies

Manish R. Patel, MD, Guillermo Garcia-Manero, MD, Ronald Paquette, MD, Shira Dinner, MD, William B. Donnellan, MD, Michael R. Grunwald, MD, Maria D Ribadeneira, PhD, Patricia Schroeder, Julie Brevard, Lindsey Wilson, Jennifer Sweeney, Patrick Kelly, MD, Jeffrey E. Lancet, MD

Blood (2019) 134 (Supplement_1): 3907.

https://doi.org/10.1182/blood-2019-124741

Published: 2019

Journal Articles

Accrual Barriers and Detection of Early Toxicity Signal in Older Less-Fit Patients Treated with Azacitidine and Nivolumab for Newly Diagnosed Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS) in the SWOG 1612 Platform Randomized Phase II/III Clinical Trial

Annette E. Hay, Sarit Assouline, MD, Roland B. Walter, MD PhD MS, Richard F. Little, MD MPH, Anna Moseley, M.S., Sperling M Gail, MPH, CHES, Annie Im, MD, James M. Foran, MD, Jerald P. Radich, MD, Min Fang, MD PhD, Megan Othus, PhD, Harry P. Erba, MD PhD, Laura C. Michaelis, MD

Blood (2019) 134 (Supplement_1): 3905.

https://doi.org/10.1182/blood-2019-124320

Published: 2019

Journal Articles

Response Rates and Quality of Life Outcomes in Australasian Leukaemia & Lymphoma Group NHL29: A Phase II Study of Ibrutinib, Rituximab and Mini-CHOP in Very Elderly Patients with Newly Diagnosed Diffuse Large B Cell Lymphoma

Emma Verner, MBBS, BMedSci,FRCPA, FRACP, Amanda Johnston, FRACP,FRCPA,MBBS,BMBS,MD, Nalini Pati, MBBS,FRACP,FRCPA, DCH, MD DNB, Eliza A Hawkes, Hui-Peng Lee, MBChB, FRACP, FRCPA, BHB, Tara Cochrane, MBBS,FRCPA,FRACP, Chan Y. Cheah, Duncan Purtill, MBBS,FRCPA,FRACP, Anoop K Enjeti, MBBS,FRCPA, FRACP,PhDMD,MRCP, Christina Brown, PhDFRACP,FRCPA,MBBS, Nicholas E. Murphy, FRCPA,MBBS,FRACP, Jennifer Curnow, MBBS, FRACP, FRCPA, PhD, Julia Carlson, Belinda Butcher, BSci, MBiostat, PhD, Judith Trotman, MBChB, FRACP, FRCPA

Blood (2019) 134 (Supplement_1): 4094.

https://doi.org/10.1182/blood-2019-124621

Published: 2019

Journal Articles

Landmark Response and Survival Analyses from 206 AML Patients Treated with Guadecitabine in a Phase 2 Study Demonstrate the Importance of Adequate Treatment Duration to Maximize Response and Survival Benefit. Survival Benefit Not Restricted to Patients with Objective Response

Karen W.L. Yee, MD, Gail J. Roboz, MD, Casey L. O'Connell, MD, Elizabeth A. Griffiths, MD, Raoul Tibes, MD PhD, Katherine J. Walsh, MD, Wendy Stock, MD, Guillermo Garcia-Manero, MD, Michael R. Savona, MD, Farhad Ravandi, MD, Naval G. Daver, MD, Elias Jabbour, MD, Todd L. Rosenblat, MD MS, Jean-Pierre Issa, MD, Xiang Yao Su, PhD, Mohammad Azab, MD, Hagop M. Kantarjian, MD

Blood (2019) 134 (Supplement_1): 3846.

https://doi.org/10.1182/blood-2019-129845

Published: 2019

Journal Articles

Copanlisib, a PI3K Inhibitor, Demonstrates a Favorable Long-Term Safety Profile in a Pooled Analysis of Patients with Hematologic Malignancies

Pier Luigi Zinzani, MD, Armando Santoro, Luigina Mollica, MD FRCPC, PhD, Sirpa Leppä, MD PhD, George A Follows, MD PhD, Georg Lenz, MD, Won Seog Kim, MD PhD, Arnon Nagler, MD MSc, Panayiotis Panayiotidis, MD, Judit Demeter, MD PhD Dr. Sci, Franck Morschhauser, MD, Javier Munoz, MD MS, FACP, Ashok Miriyala, MD, Alice Benson, PhD, Jose Garcia-Vargas, MD, Barrett H Childs, MD, Martin Dreyling, MD

Blood (2019) 134 (Supplement_1): 4009.

https://doi.org/10.1182/blood-2019-131779

Published: 2019

Journal Articles

Ten-Year Follow-up of Patients with Chronic Myeloid Leukemia Treated with Nilotinib in First-Line: Final Results of the Gimema CML 0307 Trial

Blood (2019) 134 (Supplement_1): 4145.

https://doi.org/10.1182/blood-2019-126163

Published: 2019

Journal Articles

Analysis of a Safety Run-in Cohort from Niveau, a Phase 3 Study for Patients with Aggressive Non-Hodgkin Lymphoma in First Relapse or Progression Not Eligible for High-Dose Chemotherapy (HDT), Testing Nivolumab in Combination with Gemcitabine, Oxaliplatin (GemOx) Plus Rituximab (R) in Case of B-Cell Lymphoma

Blood (2019) 134 (Supplement_1): 4085.

https://doi.org/10.1182/blood-2019-129347

Published: 2019

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Ublituximab and umbralisib in relapsed/refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia

Carfilzomib, Dexamethasone, and Daratumumab Versus Carfilzomib and Dexamethasone for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma (RRMM): Primary Analysis Results from the Randomized, Open-Label, Phase 3 Study Candor (NCT03158688)

Cytogenetic and Molecular Marker Associations to Outcomes with Duvelisib and Ofatumumab Treatment in Patients with Relapsed or Refractory CLL/SLL in the DUO Trial

An Adaptive Design Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Emapalumab in Adult Patients with Non-Primary Hemophagocytic Lymphohistiocytosis

Incidence of Vaso-Occlusive Crisis Does Not Increase with Achieving Higher Hemoglobin Levels on Voxelotor Treatment or after Discontinuation: Analyses of the HOPE Study

A Phase II Trial of Azacitidine (AZA) in Combination with Ruxolitinib (RUX) in Myelodysplastic Syndrome/Myeloproliferative Neoplasms (MDS/MPNs)

Ivosidenib (AG-120) in Patients with IDH1 -Mutant Relapsed/Refractory Myelodysplastic Syndrome: Updated Enrollment of a Phase 1 Dose Escalation and Expansion Study

Generic Versus Branded Imatinib As Frontline Therapy in Chronic-Phase Chronic Myeloid Leukemia Patients in Italy: A Case-Control Study

Real-World Treatment Patterns and Adverse Events in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib in the UK: A Preliminary Analysis

Social Media Network Utility in Disease Education: Experience from a CML-Disease Awareness Medical Education Program

Pharmacoeconomic Analysis of the Real World Treatment of Chronic Myeloid Leukemia in Chronic Phase of a Brazilian Private Institution Considering the Use of Generic Drugs and Eventual Discontinuation of Treatment

Long-Term Durability of Eltrombopag Clinical Benefit for Advanced Myelodysplastic Syndromes or Acute Myeloid Leukemia and Severe Thrombocytopenia (ASPIRE Part 3)

Effect of Avelumab to Immune Response in AML: A Phase I Study of Avelumab in Combination with Decitabine As First Line Treatment of Unfit Patients

Phase 1 Dose Escalation and Expansion Study to Determine Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the BET Inhibitor FT-1101 As a Single Agent in Patients with Relapsed or Refractory Hematologic Malignancies

Accrual Barriers and Detection of Early Toxicity Signal in Older Less-Fit Patients Treated with Azacitidine and Nivolumab for Newly Diagnosed Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS) in the SWOG 1612 Platform Randomized Phase II/III Clinical Trial

Response Rates and Quality of Life Outcomes in Australasian Leukaemia & Lymphoma Group NHL29: A Phase II Study of Ibrutinib, Rituximab and Mini-CHOP in Very Elderly Patients with Newly Diagnosed Diffuse Large B Cell Lymphoma

Landmark Response and Survival Analyses from 206 AML Patients Treated with Guadecitabine in a Phase 2 Study Demonstrate the Importance of Adequate Treatment Duration to Maximize Response and Survival Benefit. Survival Benefit Not Restricted to Patients with Objective Response

Copanlisib, a PI3K Inhibitor, Demonstrates a Favorable Long-Term Safety Profile in a Pooled Analysis of Patients with Hematologic Malignancies

Ten-Year Follow-up of Patients with Chronic Myeloid Leukemia Treated with Nilotinib in First-Line: Final Results of the Gimema CML 0307 Trial

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only